Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01874522 · ClinicalTrials.gov registry record · Phase 1
Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI
A Phase 1 study, sponsored by Taiho Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT01874522 is a Phase 1 study that has completed, run by Taiho Oncology. The registered enrollment target is 46 participants.
The verdict
NCT01874522, a Phase 1 study, has completed, sponsored by Taiho Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the bioavailability of TAS-102 tablets to an oral solution containing equivalent amounts FTD and TPI.
Interventions
- DRUG TAS-102 tablets
- DRUG TAS-102 oral solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01874522
The ClinicalTrials.gov registry entry for NCT01874522 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAS-102 tablets is the first listed.
NCT01874522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01874522 about?
NCT01874522 is a clinical study titled "Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI". The purpose of this study is to compare the bioavailability of TAS-102 tablets to an oral solution containing equivalent amounts FTD and TPI.
What is the current status of trial NCT01874522?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2013-07. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01874522?
The interventions under investigation include: TAS-102 tablets (DRUG), TAS-102 oral solution (DRUG).
Who is sponsoring clinical trial NCT01874522?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.